Elvina Almuradova: CDK4/6 inhibitor + ET as first-line standard for HR+ mBC
Elvina Almuradova, Oncology Unit Lead at Can Hospitals Turkey, shared a post on LinkedIn:
“A huge thank you to the team at Health and Pharma and Oncolife for giving me this platform to contribute and for their commitment to elevating critical conversations in healthcare. I deeply appreciate the opportunity to collaborate with such a trusted source that partners with health science and pharma professionals to bring news directly from the heart of the field.”
Elvina Almuradova is the Oncology Unit Lead at Can Hospitals Turkey and an Ambassador for the European School of Oncology. Previously, she was an Associate Professor of Oncology at the European Institute of Oncology (IEO). Her expertise encompasses basic oncology, chemotherapy, cancer biomarkers, diagnostics, and cancer cell biology.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023